Advanced search
Publication Cover
Journal of Chemotherapy Volume 26, 2014 - Issue 5
Submit an article Journal homepage
55
Views
3
CrossRef citations to date
0
Altmetric
Anticancer Original Research Papers

Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer

Zhi-Yong WuDepartment of Medical OncologyShantou Central Hospital, Shantou Hospital, Sun Yat-sen University, Shantou, GD, P.R. China
,
Hui-Hong GuanDepartment of Medical OncologyShantou Central Hospital, Shantou Hospital, Sun Yat-sen University, Shantou, GD, P.R. China
,
Ze-Xiao LinThe Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, GD, P.R. China
,
Hong-Kai YangDepartment of Medical OncologyShantou Central Hospital, Shantou Hospital, Sun Yat-sen University, Shantou, GD, P.R. China
,
Lan ZhouDepartment of Medical OncologyShantou Central Hospital, Shantou Hospital, Sun Yat-sen University, Shantou, GD, P.R. China
&
Qi-Chun CaiDepartment of Medical OncologyGuangdong General Hospital, Guangdong Academy of Medical Sciences of China, Guangzhou, GD, P.R. ChinaCorrespondence[email protected]
Pages 306-311 | Published online: 06 Dec 2013

References

  • Cappuzzo F, Novello S, De Marinis F, Selvaggi G, Scagliotti GV, Barbieri F, et al. A randomized phase II trial evaluating standard (50 mg/minute) versus low (10 mg/minute) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer. 2006;52(3):319–25.
  • Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs. 2005;16(10):1129–34.
  • Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol. 2009;4(9):1148–55.
  • Pollera CF, Ceribelli A, Crecco M, Oliva C, Calabresi F. Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs. 1997;15:115–21.
  • Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9(3):491–8.
  • Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991;27(4):258–62.
  • Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(Suppl 5):v7–12.
  • Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anti-Cancer Drugs. 1999;10(7):625–31.
  • Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C. Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest. 2003;21(5):690–4.
  • Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, et al. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol. 2006;41(1):70–6.
  • Ramalingam S, Belani CP. Carboplatin/gemcitabine combination in advanced NSCLC. Oncology (Williston Park). 2004;18 (8 Suppl 5):21–6.
  • Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005;23(33):8380–8.
  • Masters GA, Argiris AE, Hahn EA, Beck JT, Rausch PG, Ye Z, et al. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2006;1(1):19–24.
  • Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 2003;41(3):321–31.
  • Imamura F, Nishio M, Noro R, Tsuboi M, Ikeda N, Inoue A, et al. Randomized phase ii study of two schedules of carboplatin and gemcitabine for stage IIIb and IV advanced non-small cell lung cancer (JACCRO LC-01 study). Chemotherapy. 2011;57(4):357–62.
  • Hasegawa Y, Kawaguchi T, Kubo A, Ando M, Shiraishi J, Isa S, et al. Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials. J Thorac Oncol. 2011;6(11):1881–8.
  • Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol. 1997;24(Suppl 7):S7-2–7.
  • Beniwal SK, Patel KM, Shukla S, Parikh BJ, Shah S, Patel A. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer. Indian J Cancer. 2012;49(2):202–8.
  • Veltkamp SA, Beijnen JH, Schellens JH. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist. 2008;13(3):261–76.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.